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 Abstract— Bio-detection specially dedicated to distributed 
diagnostics is emerging as a quite important application for Nano-
bioelectronics. Bio-detection is required to be highly sensitive in 
order to succeed in sensing small amount of bio-markers in patient’s 
blood sample. Carbon Nanotubes (CNTs) provides devices in the 
scale of the target molecules, thereby opening up possibilities to 
sense few bio-markers. Moreover, bio-detection is also required to 
be highly specific in order to succeed in disease discrimination. FET 
technology provides control in multi-panel biochip to enhance 
specificity. The aim of the present paper is to design an array of 
Carbon Nanotube Field Effect Transistors (CNFETs) to provide 
nano-biosensing based on cytochromes P450. In particular, a novel 
CNFET biosensor array design is proposed which is robust to the 
imperfections in the CNTs thereby achieving high level of sensitivity. 
The proposed CNFET based design assures the improved specificity 
by means of a multi-gate controller at the nano-scale. The proposed 
application in distributed diagnostics is on detection of drugs in 
multi-components samples by multiplexing different P450 probes. 
I. INTRODUCTION  
IONANOSENSORS, the integration of biological processes 
and molecules with nanoscale fabricated structures, offers 
the potential for electronic control and sensing of 
biological systems [1]. To achieve this goal, we envision the 
integration of fully functional biological systems and nano-
electronics. Among such prominent technologies that are 
being investigated, Carbon Nanotube (CNT) based biosensors 
are promising devices to enhance conventional biosensors in 
terms of sensitivity, scalability and ease in realizing complex 
massive sensor arrays. We propose a Carbon Nanotube Field 
Effect Transistors (CNFETs) based array for detecting 
multiple drugs to initiate point-of-care applications in 
personalized therapy. 
      Personalization of the therapy is highly desirable when 
compared to the state-of-the-art drug therapies. Only a 
fraction of patients, typically in the 20 to 50% range, receives 
benefit in major diseases [5]. This is because of the protein’s 
polymorphism in metabolism [6] that causes over-dosing or 
under-dosing in hospitalized patients [7]. Therefore, any drug 
therapy needs to be personalized to the individual patient  [8]. 
However, only monitoring systems for genetic predisposition 
to drug metabolism are available in the market [9] while the 
mean plasma concentration after a single drug dose varies on a 
patient-by-patient basis [10] even related to environmental 
conditions and patient’s state. For these reasons, reliable 
point-of-care technologies to monitor multiple drug 
compounds in patient’s plasma are absolutely required in 
therapy personalization. These technologies have to be offered 
at a low cost while keeping them simple to succeed in 
distributed diagnostics.    
      CNFET based bio sensors are very promising to fill the 
gap needed by the tools for personalized therapy. 
Nevertheless, several challenges remain. First, it is desired to 
reliably fabricate devices which are robust to imperfections 
resulted from the state-of-the-art CNT synthesis technique [2, 
3]. This mainly requires CNFETs which are tolerant to the 
presence of metallic CNTs [4, 20] and which are robust to 
mispositioned CNTs [2, 3]. Second, new strategies to integrate 
several specifically-targeted sensing-probes on CNFET array 
have to be developed. This integration addresses new design 
flow and tools required in personalized therapy. 
      The aim of the present paper is to address these open 
challenges both on imperfection immune systems and on bio-
probes integration strategies. The rest of the paper is 
organized as follows. Section 2 deals with the detection 
principle; Section 3 gives a quick background on P450 multi-
panel sensors for bio-medical applications; Section 4 explains 
the CNFET synthesis to realize a robust CNFET-P450 sensor 
array; Section 5 describe a multiple drug detection employing 
eight-nodes CNFET-P450 sensor array; Section 6 summarize 
the paper conclusions. 
II. CNFET BASED SENSOR CONFIGURATION 
     The representative CNFET-P450 sensor configuration is 
shown in Figure 1. Highly doped (p+) CNTs over the bulk 
form the channel between the source and drain contacts, 
where as the intrinsic CNT region under the gate is controlled 
by the gate voltage [21]. Turning-on the transistor while 
exposing the CNT-channel to a P450 solution leads to 
electrostatic drift [12] of P450 cytochromes towards the  
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Figure 1. (a) Carbon Nanotube Field Effect Transistor with 
P450s bonded to the CNTs. (b) Top view of p-type CNFET  
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 nanotubes. The coupling between nanotubes and P450 
cytochromes is assured by physical adsorption onto carbon 
nanotubes [14] or by chemical bonding [12]. As 
schematically shown in Figure 2, the presence of drug 
molecules which are targets of the P450 probe-proteins leads 
to charge transfer from the CNT channel to the protein. 
Similar charge transfer may be observed from proteins to the 
CNT by reversing the bias potential enabling the redox 
reaction on the drug. 
       Each protein needs two electrons in order to detect the 
single drug molecule. The P450 protein may receive these 
two electrons only if the CNT channel is operating by a 
proper gate voltage. As a consequence the charge transfers to 
the CNT shifts the DC towards more positive (electron 
donation from the drug to the CNT channel in the presence of 
target drug) or negative (hole donation from the drug to the 
CNT channel in the presence of the same drug but in reversed 
redox potential) gate voltages. Higher sensitivity can be 
achieved by maximizing the shift in the DC curve. This could 
be achieved by pushing the channel length to the maximum 
as observed in the case of 800 nm-long CNT channel bonded 
to Streptavidin molecule to detect DNA duplex formation 
[19].     
III. BIO-PROBES FOR SPECIFIC DETECTION 
      New devices to measure multiple drugs concentration in 
real-time may be based on multi-panel cytochromes P450 
biochip which may detect multiple drugs directly in patient’s 
serum. However, each P450 cytochrome detects many drugs 
and different P450s may detect the same drug. Therefore, a 
special design of CNFET array logic to control the 
accessibility of each and every protein-probe, in order to 
assure multiple queries to each P450 array spots [11], is 
proposed here. The proposed approach maintains high 
reliability and low cost of experimentation meanwhile it 
improves the specificity of Hybrid-CNFET biochip in drugs 
monitoring. 
          Cytochrome P450 (also abbreviated with CYP, or 
CYP450) is a super-family of heme-proteins found in 
Bacteria, Archaea and Eukaryotes [13]. Cytochromes P450 
are involved in metabolism of a plethora of both exogenous 
and endogenous compounds. Most P450s metabolize multiple 
substrates, and many catalyze multiple reactions, which 
accounts for their central importance in metabolizing the 
potentially endless variety of endogenous and exogenous 
molecules. In drug metabolism, cytochrome P450 is probably 
the most important proteins of oxidative metabolism pathways 
in humans. In this context, the metabolism is any modification 
or degradation of chemicals including drugs and other 
endogenous compounds. 
 
          The whole cytochromes P450 family is capable of 
metabolizing a vast number and variety of organic substrates, 
estimated to be in the region of 200,000 chemicals or more, 
and involving around 60 distinct classes of biotransformation 
reactions. Metabolism mediated by cytochrome P450 enzymes 
plays a key role in the development of new drugs and in 
individual drug therapy. Thus, different P450 cytochromes 
may be considered to develop a multi-panel biochip for 
detection of multiple drugs content in human serum. Different 
P450 proteins detect different drugs. For example, the P450 
isoform called 2B4 detects the benzphetamine (BZ), 
aminopyrine (AP) and 7-pentoxyresorufin (PX). The 
benzphetamine is an anoretic compound closely related to 
amphetamine. It is often used in anti-obesity therapy. The 
aminopyrine is a drug with analgesic, anti-inflammatory, and 
antipyretic properties. The 7-pentoxyresorufin is indicated for 
infections, hischemia, hypertrophy, obesity, etc. Another 
example is by the isoform P450 3A4 which may be used to 
detect cyclophosphamide (CP), dextromethorphane (DX) and 
midazolam (MZ). Cyclophosphamide is an anti-cancer agent; 
dextromethorphane is an analgesic, while midazolam is a 
benzodiazepine derivative with powerful anxiolytic, amnestic, 
hypnotic, anticonvulsant, skeletal muscle relaxant and 
sedative properties.  
      These two P450 isoforms are clear examples of proteins 
which may be used as probe enzymes in CNFET based 
biochip to obtain a multiple-drugs monitoring system. In the 
present paper, all the P450 proteins present in Table 1 are 
considered in order to propose an innovative design of a P450 
based biochip for multiple-drugs detection based on CNFET 
logic. It is well know that the carbon nanotubes enhance the 
detection sensitivity in P450 based biosensors [11, 14, 16, 17]. 
Thus, functionalizing a CNFET by using the proper P450 
isoform is used to obtain both an improvement in drugs 
detection and a control of each single probe thanks to the FET 
gate, as shown in Figure 3. 
 
Figure 2 CNFET sensor functionalized by P450 2B4 to 
detect the benzphetamine, a powerful anoretic compound. 
         
 
Table 1: Interaction map of the biochip P450 cytochromes and the target molecules considered in this study. 
 
P450-1A2 P450-3A4 P450-2B4 P450-2B6 P450-2C19 P450-2C9 P450-2D6 P450-2E1 
Anti-
hypertensive 
Macrolide 
antibiotics 
Anti-
inflammatories 
Anti-cancer 
agents 
Anti-
epileptics 
Hypo-glycemic 
agents 
Beta blockers Anesthetics
- Anti-
arrhythmics 
Anti-obesity  - Angiotensin-II 
blockers 
Anti 
depressants 
- 
- HIV 
Antivirals 
-  - Anti-
inflammatories 
antipsychotics - 
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  Figure 3. CNFET-P450 Sensor Array of index four (CSA4) (a) Ideal case (b) A p-type CNFET array prone to CNT 
imperfections (metallic -in red- and misaligned CNTs) (c) Effect of imperfections on the CSA (d) CSA immune to CNT defects. 
 
IV.    CNFET-P450 SENSOR ARRAY FOR MULTI-DRUG 
DETECTION 
A. Ideal CNFET-P450 Sensor Array 
    An ideal CNFET Sensor Array (CSA) for multi-drug 
detection comprises of multiple gates as shown in the Figure 
3a. As a first step to build the CNFET array, semiconducting 
CNTs are grown or transferred to a substrate. The four gates 
(G1, G2, G3 and G4) and the contacts are then defined using 
lithography. Next, the CNTs are doped p-type with the gates 
masking the CNT segments under them thereby forming a 
CNFET Array (CA) having four control gates. The CNTs 
spanning under the four gates are distinct and hence the gates 
have independent control over the current flowing between the 
two electrodes. The one-to-one binding of P450 cytochromes 
and the gates is performed by activating each gate at a time 
while exposing the CNT channel to the respective P450 
solution. During the exposure of a specific protein solution, 
respective P450 isoform is trapped onto the proper CNTs 
bundle driven by the single gate by using protein electrostatic 
trapping [12]. For example, applying an input code of 0111 
(G1 = 0; G2 = G3 = G4 = 1) to the CNFET array while 
exposing the array to solution containing P450-1A2 results in 
binding P450-1A2 to the doped-CNT segments spanning the 
gate G1. Iterating this step by activating one gate at a time 
will result in a CSA. 
B. Impact of CNT Imperfections on the Sensor Array 
    Current CNT synthesis techniques are prone to many 
variations and imperfections in CNT parameters. The two 
major challenges that have a huge impact on the functionality 
and sensitivity of CSA are the presence of metallic CNTs and 
mispositioned CNTs. Current CNT synthesis techniques yield 
around 30% metallic CNTs [15]. Although recent work has 
demonstrated growth/transfer of aligned CNTs [18], the 
probability of a few CNTs being mispositioned is non-
negligible. Figure 3b shows a realistic scenario with 
considerable number of metallic CNTs and a few 
mispositioned CNTs. Mispositioned CNTs tend to be 
completely doped, as these CNTs are not located under the 
gates, thereby shorting the two electrodes. On the other hand, 
even metallic CNTs short circuit the two electrodes.   
     Quantifying the defective CNTs, i.e., sum of metallic and 
mispositioned CNTs, yields around 40-50% CNTs in the 
CNFET array which short circuit the two electrodes. 
Consequently, when the CA is subjected to different input 
codes to bind the four gates with respective P450s, the 
defective CNTs bind all the four P450s (Figure 3c). This 
behavior leads to reduced specificity of the CSA on drug 
detection. 
C.  Imperfection Immune CNFET Sensor Array 
    The presence of misaligned and metallic CNTs lead to 
reduced sensitivity of the CSA towards the drug. Hence a 
CSA, robust to major imperfections is vital for realizing a 
reliable biochip. Etching out the CNTs at the crucial region 
provides immunity against misaligned CNTs [2]. Figure 3d 
demonstrates the introduction of etched regions on the 
CNFET array to nullify the effect of the two misaligned 
CNTs. This step does not need any additional lithography step 
prior to the formation of the array. The array comprises of the 
pCNFETs and the metallic-CNTs. Giving an input gate code 
of 1111 (G1 = G2 = G3 = G4 = 1) while applying high voltage 
between the two electrodes burn away all the metallic-CNTs. 
At this stage, we obtain a robust CNFET array. The binding of 
P4501, P4502, P4503 and P4504 to the gates (G1, G2, G3 and 
G4) is done by activating each gate at a time {(t0, 0111), (t1, 
1011), (t2, 1101), (t3, 1110)} while exposing the CNT 
channel to the respective P450 solution. 
V. MULTIPLE DRUG DETECTION 
     As listed in Table 1, different P450 isoforms have the same 
drug compound as substrate and different drugs are substrates 
of the same P450 protein. A possible array design to 
immobilize P450s for sensing multiple drugs has to consider 
redundancy and multiple enzyme-substrate interactions. A 
CSA with the eight different P450 isoforms presented in Table 
1 is shown in Figure 4. Figure 4a is a direct physical extension 
of the CSA4 presented in the previous section. The main 
constraint while stacking several gates in between two 
electrodes is the distance between the two electrodes.  The 
distance between two electrodes should be less than the 
average CNT length grown over a substrate. However, area 
efficient design can be obtained folding the layout as shown in 
the Figure 4b. On the other hand, the number of P450s bonded 
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 per gate is directly proportional to the area of the doped-CNT 
region, which is higher for the CSA8 in Figure 4a when 
compared to 4b. Moreover, the sensitivity of the CSA is 
proportional to the amount of P450s bonded to the conducting 
CNTs. Hence with the above presented analysis, an optimal 
number of gates stacked between the two electrodes could be 
analytically derived aiming towards optimizing area for a 
desired sensitivity level. In this case, we present CSA8 
(CNFET Sensor Array of index eight) with which we can 
monitor multiple drugs. Moreover, the designed CSA8 
enables dynamic spot query which may be used to improve 
 
Figure 4. CNFET Sensor Array with eight probes (CSA8) (a) 
CSA8 with two electrodes. (b) CSA8 with three electrodes. 
 
drugs specificity in case of multiple P450-drug interactions 
[11].  In case of samples having more drugs, different CNFET 
channels will give signals related to drugs detection. 
Independent query, activating a single channel, is realized by 
giving an appropriate input code to the gates of the array.   
                In such a manner, sub-sequent queries to the same channel 
are used to distinguish different drugs giving signals in 
different probes. For example, Table 1 shows that anti-
inflammatory compounds have an influence on both 2B4 and 
2C9, hence a signal can be detected in G3 and G5. In case of 
signals from both these channels, a second query to the array 
by using slightly different polarity between the CNT-channel 
and the sample solution may enable us to distinguish between 
anti-inflammatory, anti-obesity and hypo-glycemics 
compounds.  In case of 2C9 based detection, the ability to 
distinguish diclofenac, an anti-inflammatory compound, from 
the torsemide, a well known diuretic, is in 22 mV in the 
current peak position [18]. Therefore, multiple query of 
differently polarized CNFET channel with different bias 
potentials improves the specificity in drugs detection. The 
simple design flow, mentioned above, enable us to solve the 
covering problem between the P450 cytochromes (probes) and 
the drugs (targets) and show how the presented CNFET sensor 
array platform can be employed to succeed on it. The 
optimum algorithm should sense the drugs with a minimum 
number of queries. The query list is generated by the firmware 
tools which accounts for the biochips design (the list of 
probes) and then sent to the sensor gates the input codes (8 bit 
in this example).    
VI. CONCLUSION 
       In the present paper, we investigated a multi-panel 
CNFET biochip design for detecting different drugs present in 
patients’ sample. As a future work we plan to setup the design 
flow for simulating the configuration of the CNFET array 
with different P450s, eventually leading towards practical 
implementation of the sensor array. Such a sensor array 
enables early identification of drug candidates and it opens up 
new applications in personalization of drugs-therapy. The 
potential socio-economical relevance of a similar CNFET 
biochip technology is envisaged in a huge positive impact on 
different items: improvement of drugs efficacy, improvement 
of life quality of patients, diminishing of medical care 
expenses as well as shortening the time-to-market for new 
drug development. In fact, it may provide a unique and 
innovative solution for new tools in pharmacokinetic studies 
both in animals and humans. These new tools may open the 
possibility for shortening the typically 1-2 months now 
available with current measurement methods (e.g., 
LCMS/MS). The proposed CNFET sensor array inherently 
has the multiplexing nature as opposed to the sequential 
operation of the current methods. Therefore, an optimal use of 
such a multi-panel biochip may accelerate drug development 
by several months, and it will save costs for analytics by 
orders of magnitude. 
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